QuicksortRx

Quarterly Report

Q1 2025

ALL-TIME SAVINGS	Q1 2025 TOTAL SAVINGS	AVG. Q1 2025 HOSPITAL SAVINGS
$190M	**$21.2M**	**$472k**
📈 **+12.6% QoQ**	📈 **+13.3% QoQ**	📈 **+3.2% QoQ**

Q1 Savings by Initiative

Savings for all customers

63% | 825 Product Swaps — **$13.4M** Savings

22% | 78 Contract Savings — **$4.73M** Savings

11% | 117 Accumulation Fixes — **$2.25M** Savings

4% Other Savings — **$834k** Savings

Customer Leaderboard
Q1 Savings

| 🏅	💰	📍	🛏️
1.	$2.8M	W	1.8k
2.	$1.2M	S	1.3k
3.	$1.1M	MW	930
4.	$1.0M	MW	10.5k
5.	$943k	PNW	1k

Product Utilization

9k sessions on the QuicksortRx platform (📈 **+29.9% QoQ**) in Q1 2025.

Customers spent an average of **21 minutes** per session.

WAC Premium Performance

Average WAC Premium of 3.21% across all health systems.

Average: **3.21%**
Median: **2.69%**

2% CLUB

The 2% Club welcomed **1 new member**, raising our total customers with this club status to 26.

2% Club Member

QuicksortRx

QuicksortRx

Quarterly Report
Q1 2025

HEALTH SYSTEMS	MANAGED SPEND	Q1 CUSTOMER ADVISORY CALLS
46	**$18.8B**	**402**
📈 +12.2% QoQ	📈 +15.8% YoY	📞

Chart legend: ■ All-Time Savings ■ Customers

Y-axis (left): $0, $50M, $100M, $150M, $200M
Y-axis (right): 10, 20, 30, 40, 50
X-axis: Q1 2024, Q2 2024, Q3 2024, Q4 2025, Q1 2025

HIGHEST	Q1 ROI	AVERAGE
42		**15**

FASTEST Q1	LAUNCH TIMING	AVG P2Y
36 Days		**42** Days

In The News

Defined the industry. Still leading it.

BEST IN KLAS — PURCHASING OPTIMIZATION ANALYTICS 2025

KLAS ranks QuicksortRx as the **#1 product** for Purchasing Optimization Analytics in the 2025 Best in KLAS Awards.

QuicksortRx is the only product in the category for which 100% of customers reported:

- Avoids charging for every thing
- Keeps all promises
- Is part of their long-term plans
- Is a product they will buy again

Learn more: quicksortrx.com/klas

New Releases

QuicksortRx 340B Benefit
Prepare for potential 340B policy changes by assessing impacts on your unique pharmacies and suppliers.

- **340B Benefit**: Know the financial impact of the existing 340B program and potential changes overtime.
- **340B Rebate Exposure**: Define potential cash requirements for new supplier rebate models.

Biosimilar Comparisons
Outpatient groups now get alerts for any biosimilar substitutions that could significantly boost Medicare revenue.

New To The Team

Tom Nally
Vice President, Finance

Earnie Broughton
Senior Software Engineer

Brandon Underwood
Senior Software Engineer

Gabi Rubino
Executive Coordinator

Erin Corcoran
Executive Coordinator

QuicksortRx